Whole Genome Sequencing Market Size, Share, Forecast, & Trends Analysis by Offering (Library Preparation, DNA Extraction) Sequencing Type (Large, Small, Phased), Technology (SBS, SMRT, Nanopore, Nanoball) Application, End User – Global Forecast to 2031

Whole Genome Sequencing Market Size, Share, Forecast, & Trends Analysis by Offering (Library Preparation, DNA Extraction) Sequencing Type (Large, Small, Phased), Technology (SBS, SMRT, Nanopore, Nanoball) Application, End User – Global Forecast to 2031

Whole Genome Sequencing Market Size, Share, Forecast, & Trends Analysis by Offering (Library Preparation, DNA Extraction) Sequencing Type (Large, Small, Phased), Technology (SBS, SMRT, Nanopore, Nanoball) Application, End User – Global Forecast to 2031

The global whole genome sequencing market is projected to reach $7.17 billion by 2031 at a CAGR of 15.2% from 2024 to 2031.

Succeeding extensive secondary and primary research and in-depth analysis of the market scenario, the report comprises the analysis of key industry drivers, restraints, challenges, and opportunities. The growth of the spirometers market is driven by the declining costs of sequencing, the increasing prevalence of cancer & genetic disorders, the growing utilization of whole genome sequencing in disease diagnostics & precision medicine, increasing pharmaceutical R&D expenditures, improvements in regulatory & reimbursement scenarios for whole genome sequencing, rising healthcare expenditures, increasing funding for research activities, the growing need for the early detection & prevention of diseases, technological advancements in sequencing products, and government initiatives promoting the use of sequencing in clinical & research applications. However, the high costs of whole genome sequencing consumables, the low chances of identifying positive, actionable mutations for precision medicine, and the ethical & legal issues related to whole genome sequencing-based diagnosis restrain the growth of this market.

Furthermore, increasing applications of whole genome sequencing, government support for large-scale genomic sequencing projects, and emerging economies are expected to generate growth opportunities for the players operating in this market. However, the uncertainties in the regulatory landscape, the limited expertise & sequencing capabilities of small & medium-sized laboratories, the lack of sequencing professionals in developing countries, and the high capital investments required for NGS setups pose a major challenge to market growth.

The report offers a competitive landscape based on an extensive assessment of the product portfolio offerings, geographic presences, and key strategic developments adopted by leading market players in the industry over four years (2021–2024). The key players operating in the global whole genome sequencing market are Illumina, Inc. (U.S.), Thermo Fisher Scientific, Inc. (U.S), QIAGEN N.V. (Netherlands), F. Hoffmann-La Roche Ltd (Switzerland), PerkinElmer, Inc. (U.S) Agilent Technologies, Inc. (U.S), Pacific Biosciences of California Inc. (U.S), Danaher Corporation (U.S), Bio-Rad Laboratories, Inc. (U.S.), Oxford Nanopore Technologies Plc. (U.K),MGI Tech Co., Ltd. (China), Beijing Genomics Institute (BGI) (China).

Among all the offerings studied in this report, the consumables segment is expected to account for the largest share of over 70.1% of the whole genome sequencing market. This segment’s large market share can be attributed to the recurring use of consumables, continuous advancements in reagents and target enrichment protocols and associated consumables, and the increasing applications of whole genome sequencing in clinical settings.

Among all the sequencing types studied in this report, in 2024, the whole genome sequencing segment is expected to account for the largest share of the whole genome sequencing market. This segment’s large market share can be attributed to the large whole genome sequencing provides high resolution and base-by-base view of the genome and helps in sequencing large genome for providing population-level studies.

Among all the technologies studied in this report, in 2024, the sequencing by synthesis segment is expected to account for the largest share of the whole genome sequencing market. This segment’s large market share can be attributed to the widespread adoption of sequencing by synthesis technology, which offers high accuracy and supports both paired-end and single-read libraries, enabling high-resolution genome sequencing.

Among all the applications studied in this report, in 2024, the research applications segment is expected to account for the largest share of the whole genome sequencing market. This segment’s large market share is attributed to the increasing use of whole genome sequencing to identify novel drug targets, the rising demand for gene-based medicines, and growing investments in drug research and development activities.

Among all the end users studied in this report, in 2024, the pharmaceutical & biotechnology companies segment is expected to account for the largest share of the whole genome sequencing market. This segment’s large market share can be attributed to increased R&D spending by pharmaceutical and biotechnology firms, along with the rising incidence of genetic diseases, which is fueling the adoption of whole genome sequencing in these industries.

An in-depth analysis of the geographical scenario of the global whole genome sequencing market provides detailed qualitative and quantitative insights into the five major geographies (North America, Europe, Asia-Pacific, Latin America, and the Middle East & Africa) along with the coverage of major countries in each region. In 2024, North America is expected to account for the largest share of over 52.1% of the whole genome sequencing market. In the region in 2024, the U.S. is expected to account for the largest share of the whole genome sequencing market in North America. North America’s significant market share can be attributed to factors such as high awareness of whole genome sequencing, favorable government initiatives supporting genomics research, increasing applications of NGS-based research, decreasing sequencing costs, a high prevalence of cancer, and a supportive reimbursement scenario.

Scope of the Report:

Whole Genome Sequencing Market Assessment— by Offering

Consumables
Sample Preparation Kits & Reagents
Nucleic Acid Extraction & Amplification
Library Preparation & Target Enrichment
Quality Control
Other Consumables
Instruments
Software
Services

Note: Other consumables include vials, pipettes, containers, trays, sequencing reagents, flow cells, and tubes.

Whole Genome Sequencing Market Assessment— by Sequencing Type

Large Whole-Genome Sequencing
Small Whole-Genome Sequencing
Human Whole-Genome Sequencing
Other Whole-Genome Sequencing Types

Note: Other Whole-genome sequencing types include De novo sequencing, Phased sequencing, Long-read sequencing, and Clone-by-clone sequencing.

Whole Genome Sequencing Market Assessment— by Technology

Sequencing by Synthesis
Ion Semiconductor Sequencing
DNA Nanoball Sequencing
Single-molecule Real-time Sequencing
Other NGS Technologies

Note: Other whole genome sequencing technologies include nanopore sequencing and AVITI sequencing (Avidity base chemistry (ABC).

Whole Genome Sequencing Market Assessment—by Application

Research and Other Applications
Drug Discovery
Agriculture and Animal Research
Other Applications
Clinical Applications
Reproductive Health
Oncology
Infectious Diseases
Other Clinical Applications

Note: Other applications include food microbiology, microbiota analysis in the beverage industry, and environmental studies.

Other clinical applications include the detection of genetic aberrations in neurological disorders, rare diseases, metabolic and immune disorders, and food-borne illnesses.

Whole Genome Sequencing Market Assessment—by End User

Pharmaceutical & Biotechnology Companies
Hospitals & Diagnostic Laboratories
Academic Institutes & Research Centers
Other End Users

Note: Other end users primarily include forensic laboratories & security agencies, food & beverage companies, and agriculture companies.

Whole Genome Sequencing Market Assessment—by Geography

North America
U.S.
Canada
Europe
Germany
France
U.K
Italy
Spain
Rest of Europe (RoE)
Asia-Pacific
Japan
China
India
Australia
South Korea
Rest of Asia-Pacific (RoAPAC)
Latin America
Brazil
Mexico
Rest of Latin America (RoLATM)
Middle East & Africa

Whole Genome Sequencing Market - Report Summary

Report Metrics	Details
Years Considered	2022 - 2031
Base Year	2031
Forecast Period	2024-2031
Page Count	312
Units Referenced	Value (USD Million)
Segments/Key Topics	Market by Offering, Sequencing Type, Technology, Application, and End User
Regions Covered	North America, Europe, Asia-Pacific, Latin America, and Middle East & Africa
Key Companies Mentioned	Illumina, Inc. (U.S.), Thermo Fisher Scientific, Inc. (U.S), QIAGEN N.V. (Netherlands), F. Hoffmann-La Roche Ltd (Switzerland), PerkinElmer, Inc. (U.S) Agilent Technologies, Inc. (U.S), Pacific Biosciences of California Inc. (U.S), Danaher Corporation (U.S), Bio-Rad Laboratories, Inc. (U.S.), Oxford Nanopore Technologies Plc. (U.K), MGI Tech Co., Ltd. (China), Beijing Genomics Institute (BGI) (China)

FAQs About the Report

What is the focus of the whole genome sequencing market study?

The global whole genome sequencing market report covers the qualitative analysis and market sizing of the market based on offering, sequencing type, technology, application, and end user. This report involves the analysis of various segments of whole genome sequencing at the regional and country level. The report also provides insights on factors impacting market growth, regulatory analysis, pricing analysis, and Porter’s five forces analysis.

What is the revenue generated from the sales of whole genome sequencing solutions across the globe?

The global whole genome sequencing market is projected to reach $7.17 billion by 2031 at a CAGR of 15.2% from 2024 to 2031.

Which offering is estimated to hold the major share of the market in 2024?

Among all the offerings studied in this report in 2024, the consumables segment is expected to account for the largest share of the whole genome sequencing market. The largest share of this segment is attributed to advancements in kits and reagents, increasing prevalence of genetic disease, rising healthcare expenditure, and declining sequencing costs.

Which technology is estimated to hold the major share of the market in 2024?

Among all the technologies studied in this report, in 2024, the sequencing by synthesis segment is expected to account for the largest share of the whole genome sequencing market. This technology provides long-insert paired-end reads for de novo sequencing and sequence assembly and supports both paired-end and single-read libraries. Additionally, its cost-effectiveness and high-resolution genome sequencing capabilities have driven its widespread adoption, contributing to its dominant position in the market.

What are the key factors supporting the growth of this market? Also, what are the major opportunities for existing market players and new entrants in the global whole genome sequencing market?

The growth of this market can be attributed to the increasing prevalence of genetic disorders, rising healthcare expenditure, declining cost of sequencing, increasing pharmaceutical R&D expenditures, expanding clinical applications of whole genome sequencing, technological advancements in sequencing procedures, advantages of whole genome sequencing such as high-resolution, and base-by-base view of the genome.

Furthermore, government initiatives supporting large-scale genomic sequencing projects, the rising adoption of bioinformatics and genomic data management solutions, and the increasing number of whole genome sequencing projects are expected to offer significant market growth opportunities.

Who are the major players operating in the global whole genome sequencing market?

The key players operating in the whole genome sequencing market are Illumina, Inc. (U.S.), Thermo Fisher Scientific, Inc. (U.S), QIAGEN N.V. (Netherlands), F. Hoffmann-La Roche Ltd (Switzerland), PerkinElmer, Inc. (U.S) Agilent Technologies, Inc. (U.S), Pacific Biosciences of California Inc. (U.S), Danaher Corporation (U.S), Bio-Rad Laboratories, Inc. (U.S.), Oxford Nanopore Technologies Plc. (U.K), MGI Tech Co., Ltd. (China), Beijing Genomics Institute (BGI) (China).

Which regions/countries are likely to offer significant growth opportunities for the vendors in this market during the analysis period?

Countries like China and India are expected to present significant growth opportunities for market vendors, driven by factors such as the expanding healthcare and pharmaceutical sectors, the rising prevalence of genetic disorders, increasing government initiatives and funding for genomic research, and improvements in healthcare infrastructure.